首页> 外文期刊>CNS oncology. >Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients
【24h】

Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients

机译:肿瘤治疗领域和替莫唑胺对新诊断成胶质母细胞瘤患者的终生生存获益估计

获取原文
       

摘要

Aim: To estimate the mean lifetime survival benefit, an essential component of health economic evaluations in oncology, of adding tumor treating fields (TTFields) to maintenance temozolomide (TMZ) for newly diagnosed glioblastoma patients. Methods: We integrated EF-14 trial data with glioblastoma epidemiology data. The model provided for an evidence-based approach to estimate lifetime survival for the material number of EF-14 trial patients still alive at 5 years. Results & conclusion: Patients treated with TTFields and TMZ had an incremental mean lifetime survival of 1.8 years (TTFields/TMZ: 4.2 vs TMZ alone: 2.4). Patients alive at year 2 after starting TTFields had a 20.7% probability of surviving to year 10. The results presented here provide the required incremental survival benefit necessary for a future assessment of the incremental cost–effectiveness of TTFields.
机译:目的:评估平均生存期收益,这是肿瘤学健康经济评估的重要组成部分,为新诊断的胶质母细胞瘤患者在维持替莫唑胺(TMZ)中添加肿瘤治疗区域(TTField)。方法:我们将EF-14试验数据与胶质母细胞瘤流行病学数据进行了整合。该模型提供了一种基于证据的方法,可以估算5年后仍活着的EF-14试验患者的材料生存期。结果与结论:接受TTFields和TMZ治疗的患者的平均生存期延长了1.8年(TTFields / TMZ:4.2,而单独的TMZ:2.4)。开始使用TTFields后第2年存活的患者存活至10年的可能性为20.7%。此处提供的结果为将来评估TTFields的增量成本-效果提供了所需的增量生存利益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号